Gelesis Holdings (Gelesis Holdings) EV-to-Revenue : 4.46 (As of May. 05, 2024)

View and export this data going back to 2022. Start your Free Trial

What is Gelesis Holdings EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Gelesis Holdings's enterprise value is $54.12 Mil. Gelesis Holdings's Revenue for the trailing twelve months (TTM) ended in Jun. 2023 was $12.14 Mil. Therefore, Gelesis Holdings's EV-to-Revenue for today is 4.46.

The historical rank and industry rank for Gelesis Holdings's EV-to-Revenue or its related term are showing as below:

GLSHQ' s EV-to-Revenue Range Over the Past 10 Years
Min: 2.35 Med: 5.52 Max: 46.61
Current: 4.43

During the past 2 years, the highest EV-to-Revenue of Gelesis Holdings was 46.61. The lowest was 2.35. And the median was 5.52.

GLSHQ's EV-to-Revenue is not ranked
in the Biotechnology industry.
Industry Median: 7.98 vs GLSHQ: 4.43

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-05-05), Gelesis Holdings's stock price is $0.0021. Gelesis Holdings's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2023 was $0.17. Therefore, Gelesis Holdings's PS Ratio for today is 0.01.

Gelesis Holdings EV-to-Revenue Historical Data

The historical data trend for Gelesis Holdings's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gelesis Holdings EV-to-Revenue Chart

Gelesis Holdings Annual Data

Trend

Dec21

Dec22

EV-to-Revenue

3.44

Gelesis Holdings Quarterly Data
	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23
EV-to-Revenue	Get a 7-Day Free Trial					5.95	4.72	3.44	4.13	5.73

Competitive Comparison of Gelesis Holdings's EV-to-Revenue

For the Biotechnology subindustry, Gelesis Holdings's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Gelesis Holdings's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Gelesis Holdings's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Gelesis Holdings's EV-to-Revenue falls into.

Gelesis Holdings EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Gelesis Holdings's EV-to-Revenue for today is calculated as:

EV-to-Revenue	=	Enterprise Value (Today)	/	Revenue (TTM)
	=	54.120	/	12.14
	=	4.46

Gelesis Holdings's current Enterprise Value is $54.12 Mil.
Gelesis Holdings's Revenue for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $12.14 Mil.

Gelesis Holdings (OTCPK:GLSHQ) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Gelesis Holdings's PS Ratiofor today is calculated as:

PS Ratio	=	Share Price (Today)	/	Revenue per Share (TTM)
	=	0.0021	/	0.166
	=	0.01

Gelesis Holdings's share price for today is $0.0021.
Gelesis Holdings's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.17.

Gelesis Holdings EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Gelesis Holdings's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Gelesis Holdings (Gelesis Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Gelesis Holdings Inc (OTCPK:GLSHQ) » Definitions » EV-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

501 Boylston Street, Suite 6102, Boston, MA, USA, 02116

Website

https://www.gelesis.com

Gelesis Holdings Inc is a biotherapeutics company advancing a novel category of treatments for weight management and gut related chronic diseases. Its portfolio includes Plenity, an FDA-cleared product to aid in weight management, as well as potential therapies in development for patients with Type 2 Diabetes, Non-alcoholic Fatty Liver Disease (NAFLD)/Non-alcoholic Steatohepatitis (NASH), and Functional Constipation.

Executives

Raju S Kucherlapati	director	77 LOUIS PASTEUR AVENUE, BOSTON MA 02115
Bomsmaster Llc	10 percent owner	195 CHURCH STREET, 15TH FLOOR, NEW HAVEN CT 06510
Paul R. Fonteyne	director	C/O RESTORBIO, INC., 501 BOYLSTON STREET SUITE 6102, BOSTON MA 02116
Hpso Spv Ltd	10 percent owner	SARNIA HOUSE, LE TRUCHOT, ST PETER PORT Y7 GY1 4NA
Alessandro Sannino	officer: Lead Project Scientist	C/O GELESIS, INC., 501 BOYLSTON STREET, SUITE 6102, BOSTON MA 02116
Dominic Perks	director	GELESIS, INC., 501 BOYLSTON STREET, SUITE 1602, BOSTON NY 02116
David A. Pass	officer: Chief Op. & Comm. Officer	GELESIS, INC., 501 BOYLSTON STREET, SUITE 1602, BOSTON MA 02116
Elaine Chiquette	officer: Chief Scientific Officer	C/O GELESIS, INC., 501 BOYLSTON STREET, SUITE 6102, BOSTON MA 02116
Jane Wildman	director	C/O GELESIS, INC., 501 BOYLSTON STREET, SUITE 6102, BOSTON MA 02116
Harry L. Leider	officer: Chief Medical Officer	C/O GELESIS, INC., 501 BOYLSTON STREET, SUITE 6102, BOSTON MA 02116
Clayton Christopher	director	2407 S. CONGRESS AVE, SUITE E103, AUSTIN TX 78704
Health Plc Puretech	10 percent owner	6 TIDE STREET, SUITE 400, BOSTON MA 02210
Ssd2, Llc	10 percent owner	142 TEMPLE STREET, SUITE 206, NEW HAVEN CT 06511
Yishai Zohar	director, officer: President & CEO	C/O GELESIS, INC., 501 BOYLSTON ST., SUITE 6102, BOSTON MA 02116
Elon Boms	10 percent owner	C/O THIMBLE POINT ACQUISITION CORP., 195 CHURCH STREET, 15TH FLOOR, NEW HAVEN CT 06510